All In MedTech

Device Trial Radar · NCT04984629

Study of the ReGelTec HYDRAFIL System

Prospective, Single Arm, Non-randomized, Traditional Feasibility Study to Evaluate the Safety and Performance of the ReGelTec HYDRAFIL System

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Jan 4, 2022

Primary completion

Oct 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
ReGelTec, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 30, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study designed to treat patients with back pain associated with degenerative lumbar disc disease.

Conditions

  • Degenerative Disc Disease

Interventions

  • HYDRAFILDevice

    The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SuccessTime frame: post-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beam Interventional & Diagnostic Imaging

    Calgary, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.